MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Short-term Debt
Borrowings and the current portion of long-term debt due within one year.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Short-term Debt · Q1 FY2026 · quarter ended Mar 2026
Short-term debt rises 14.3% from a year ago
Short-term debt stood at $920K at the end of Q1 FY2026, up 14.3% from a year earlier and up 3.3% from the prior quarter. Over 3 fiscal years it compounded at +36.8% a year.
Context
- Short-term debt amounted to 0.2% of total assets at the end of Q1 FY2026, down 0.5 pp from a year earlier.
- Short-term debt increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term debt keeps rising in the next quarterly balance sheet after a +14.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 891K USD
- Year-over-year change
- +14.5%
- 3-year CAGR
- +36.8%
| Period | Period end | Short-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 891K | +14.5% |
| FY2024 | 2024-12-31 | 778K | +57.2% |
| FY2023 | 2023-12-31 | 495K | +42.2% |
| FY2022 | 2022-12-31 | 348K | — |
Short-term Debt vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 short-term debt of $920K is the 3rd highest of the 11 companies compared; the peer median is $0.
- Short-term debt amounts to 0.2% of total assets for MPLT, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $2.14M | — | +27.4% | 0.8% | |
| Mar 2026 | $1.46M | — | — | 0.6% | |
| Mar 2026 | $920K | +14.3% | +36.8% | 0.2% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $730K | — | — | 0.2% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $291K | — | — | 0.2% |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Jun 2026 | $0 | — | — | 0.0% | |
| Dec 2025 | $0 | — | — | 0.0% | |
| Peer median (excluding MPLT) | $0 | — | +27.4% | 0.0% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.